InsiderTrades.com logo
Adam Dubow net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Adam Dubow Biography and Net Worth

General Counsel of Day One Biopharmaceuticals

Adam Dubow joined Day One as General Counsel in October 2022 following a 22-year tenure at Bristol Myers Squibb, where he most recently served as Chief Compliance and Ethics Officer, establishing a best-in-class global compliance program.

In addition to serving on the Bristol Myers Squibb’s management team, Adam previously served as the Company’s Lead Counsel for the Global Research and Development organization. Prior to this role, he directed the Legal Teams for the Europe, Middle East & Africa, as well as the Asia Pacific and Japan Regions. He also created and led the Global Corporate Policy function at Bristol Myers Squibb.

Prior to joining Bristol Myers Squibb, Adam was a Partner at Sedgwick, Detert, Moran & Arnold, where he specialized in products liability litigation. Adam currently serves on the Global Board of the Healthcare Businesswomen’s Association. He holds an undergraduate degree from Brandeis University, and a J.D. from Fordham University School of Law. Adam is a member of the New York State Bar.

What is Adam Dubow's net worth?

The estimated net worth of Adam Dubow is at least $522.30 thousand as of November 17th, 2025. Mr. Dubow owns 62,626 shares of Day One Biopharmaceuticals stock worth more than $522,301 as of December 5th. This net worth evaluation does not reflect any other assets that Mr. Dubow may own. Learn More about Adam Dubow's net worth.

How old is Adam Dubow?

Mr. Dubow is currently 57 years old. There are 4 older executives and no younger executives at Day One Biopharmaceuticals. Learn More on Adam Dubow's age.

How do I contact Adam Dubow?

The corporate mailing address for Mr. Dubow and other Day One Biopharmaceuticals executives is 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080. Day One Biopharmaceuticals can also be reached via phone at 650-484-0899 and via email at [email protected]. Learn More on Adam Dubow's contact information.

Has Adam Dubow been buying or selling shares of Day One Biopharmaceuticals?

Within the last three months, Adam Dubow has sold $38,482.29 in shares of Day One Biopharmaceuticals stock. Most recently, Adam Dubow sold 4,319 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $8.91, for a transaction totalling $38,482.29. Following the completion of the sale, the insider now directly owns 62,626 shares of the company's stock, valued at $557,997.66. Learn More on Adam Dubow's trading history.

Who are Day One Biopharmaceuticals' active insiders?

Day One Biopharmaceuticals' insider roster includes Jeremy Bender (CEO), Samuel Blackman (Insider), Adam Dubow (General Counsel), Papanek Grant (Director), Lauren Merendino (Insider), Saira Ramasastry (Director), and Charles York, II (Chief Operating and Financial Officer). Learn More on Day One Biopharmaceuticals' active insiders.

Are insiders buying or selling shares of Day One Biopharmaceuticals?

During the last twelve months, insiders at the sold shares 16 times. They sold a total of 134,085 shares worth more than $1,259,570.00. The most recent insider tranaction occured on November, 17th when insider Adam Dubow sold 4,319 shares worth more than $38,482.29. Insiders at Day One Biopharmaceuticals own 6.2% of the company. Learn More about insider trades at Day One Biopharmaceuticals.

Information on this page was last updated on 11/17/2025.

Adam Dubow Insider Trading History at Day One Biopharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2025Sell4,319$8.91$38,482.2962,626View SEC Filing Icon  
8/18/2025Sell4,365$6.77$29,551.0554,858View SEC Filing Icon  
5/16/2025Sell4,552$6.26$28,495.5247,136View SEC Filing Icon  
2/18/2025Sell4,646$11.96$55,566.1639,602View SEC Filing Icon  
8/16/2024Sell3,202$14.00$44,828.0026,928View SEC Filing Icon  
5/16/2024Sell3,253$16.08$52,308.2421,731View SEC Filing Icon  
2/16/2024Sell3,242$15.25$49,440.5016,585View SEC Filing Icon  
11/16/2023Sell5,313$11.69$62,108.9711,428View SEC Filing Icon  
See Full Table

Adam Dubow Buying and Selling Activity at Day One Biopharmaceuticals

This chart shows Adam Dubow's buying and selling at Day One Biopharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Day One Biopharmaceuticals Company Overview

Day One Biopharmaceuticals logo
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $8.34
Low: $8.21
High: $8.60

50 Day Range

MA: $8.08
Low: $6.77
High: $10.36

2 Week Range

Now: $8.34
Low: $5.64
High: $13.92

Volume

2,072,215 shs

Average Volume

2,762,046 shs

Market Capitalization

$856.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A